PDCD1 and non-small cell lung carcinoma: investigated the impact of the microbial metabolite butyrate on modifying antitumor immunity, specifically focusing on PD-1 expression on CD8+ and V9 V2 (V2+) T cells in patients with non-small cell lung cancer (NSCLC) (31).